{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:32Z","timestamp":1787027792791,"version":"build-2736575974"},"reference-count":46,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["SEP-210221188"],"award-info":[{"award-number":["SEP-210221188"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>In the context of hematopoietic stem cell (HSC) transplantation, conditioning with myelo- and immune-ablative agents is used to eradicate the patient\u2019s diseased cells, generate space in the marrow and suppress immune reactions prior to the infusion of donor HSCs. While conditioning is required for effective and long-lasting HSC engraftment, currently used regimens are also associated with short and long-term side effects on extramedullary tissues and even mortality. Particularly in patients with severe combined immunodeficiency (SCID), who are generally less than 1-year old at the time of transplantation and often suffer from existing comorbidities. There is a pressing need for development of alternative, less toxic conditioning regimens. Hence, we here aimed to improve efficacy of currently used myeloablative protocols by combining busulfan with stem-cell niche-directed therapeutic agents (G-CSF or plerixafor) that are approved for clinical use in stem cell mobilization. T, B and myeloid cell recovery was analyzed in humanized NSG mice after different conditioning regimens. Increasing levels of human leukocyte chimerism were observed in a busulfan dose-dependent manner, showing comparable immune recovery as with total body irradiation in CD34-transplanted NSG mice. Notably, a better T cell reconstitution compared to TBI was observed after busulfan conditioning not only in NSG mice but also in SCID mouse models. Direct effects of reducing the stem cell compartment in the bone marrow were observed after G-CSF and plerixafor administration, as well as in combination with low doses of busulfan. Unfortunately, these direct effects on the stem population in the bone marrow were not reflected in increased human chimerism or immune recovery after CD34 transplantation in NSG mice. These results indicate moderate potential of reduced conditioning regimens for clinical use relevant for all allogeneic transplants.<\/jats:p>","DOI":"10.3390\/cells10051077","type":"journal-article","created":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T10:53:29Z","timestamp":1619780009000},"page":"1077","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3862-165X","authenticated-orcid":false,"given":"Laura","family":"Garcia-Perez","sequence":"first","affiliation":[{"name":"Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0368-2428","authenticated-orcid":false,"given":"Lieke","family":"van Roon","sequence":"additional","affiliation":[{"name":"Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco W.","family":"Schilham","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Willem-Alexander Children\u2019s Hospital, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan C.","family":"Lankester","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Willem-Alexander Children\u2019s Hospital, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Pike-Overzet","sequence":"additional","affiliation":[{"name":"Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1588-8519","authenticated-orcid":false,"given":"Frank J. T.","family":"Staal","sequence":"additional","affiliation":[{"name":"Department of Immunology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1182\/blood-2004-03-0960","article-title":"Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen","volume":"105","author":"Rao","year":"2005","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/hum.2017.175","article-title":"Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug","volume":"28","author":"Ferrua","year":"2017","journal-title":"Human Gene Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jaci.2013.01.047","article-title":"B-cell reconstitution for SCID: Should a conditioning regimen be used in SCID treatment?","volume":"131","author":"Haddad","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.jaci.2013.03.014","article-title":"Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: Need for safer conditioning and reduced late effects","volume":"131","author":"Horn","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3389\/fped.2019.00434","article-title":"Conditioning Perspectives for Primary Immunodeficiency Stem Cell Transplants","volume":"7","author":"Shaw","year":"2019","journal-title":"Front. Pediatrics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10875-018-0540-9","article-title":"Long-Term Health Outcome and Quality of Life Post-HSCT for IL7R\u03b1-, Artemis-, RAG1- and RAG2-Deficient Severe Combined Immunodeficiency: A Single Center Report","volume":"38","author":"Slatter","year":"2018","journal-title":"J. Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.bbmt.2008.12.489","article-title":"Busulfan in hematopoietic stem cell transplantation","volume":"15","author":"Ciurea","year":"2009","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00148581-200709040-00008","article-title":"Intravenous Busulfan","volume":"9","author":"Hoy","year":"2007","journal-title":"Pediatric Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1349-7006.2004.tb03231.x","article-title":"DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect","volume":"95","author":"Iwamoto","year":"2004","journal-title":"Cancer Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation Outcomes for Severe Combined Immunodeficiency 2000\u20132009","volume":"371","author":"Pai","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.bbmt.2020.07.004","article-title":"Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy","volume":"26","author":"Bradford","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.bbmt.2019.03.008","article-title":"Low Exposure Busulfan Conditioning to Achieve Sufficient Multilineage Chimerism in Patients with Severe Combined Immunodeficiency","volume":"25","author":"Dvorak","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/j.bbmt.2019.12.589","article-title":"Early Outcome of a Phase I\/II Clinical Trial (NCT03538899) of Gene-Corrected Autologous CD34+ Hematopoietic Cells and Low-Exposure Busulfan in Newly Diagnosed Patients with Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID)","volume":"26","author":"Cowan","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1182\/blood-2006-07-029090","article-title":"Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell\u2013immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype","volume":"109","author":"Carlier","year":"2007","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1182\/blood-2019-123432","article-title":"Lentiviral Gene Therapy with Autologous Hematopoietic Stem and Progenitor Cells (HSPCs) for the Treatment of Severe Combined Immune Deficiency Due to Adenosine Deaminase Deficiency (ADA-SCID): Results in an Expanded Cohort","volume":"134","author":"Kohn","year":"2019","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month post-transplant CD4 count predict survival and immune recovery: A PIDTC retrospective study","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood-2013-01-476432","article-title":"SCID patients with ARTEMIS vs. RAG deficiencies following HCT: Increased risk of late toxicity in ARTEMIS-deficient SCID","volume":"123","author":"Schuetz","year":"2014","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"607926","DOI":"10.3389\/fimmu.2020.607926","article-title":"Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency","volume":"11","author":"Villa","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-01-0061","article-title":"Competition within the early B-cell compartment conditions B-cell reconstitution after hematopoietic stem cell transplantation in nonirradiated recipients","volume":"108","author":"Liu","year":"2006","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.3389\/fimmu.2019.02680","article-title":"Delineating Human B Cell Precursor Development With Genetically Identified PID Cases as a Model","volume":"10","author":"Wentink","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/leu.2012.17","article-title":"Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation","volume":"26","author":"Winkler","year":"2012","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chevaleyre, J., Duchez, P., Rodriguez, L., Vlaski, M., Villacreces, A., Conrad-Lapostolle, V., Praloran, V., Ivanovic, Z., and Brunet de la Grange, P. (2013). Busulfan Administration Flexibility Increases the Applicability of Scid Repopulating Cell Assay in NSG Mouse Model. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074361"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10875-010-9478-2","article-title":"Human B Cell Development and Antibody Production in Humanized NOD\/SCID\/IL-2R\u03b3null (NSG) Mice Conditioned by Busulfan","volume":"31","author":"Choi","year":"2011","journal-title":"J. Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/biores.2014.0008","article-title":"Sustained Engraftment of Cryopreserved Human Bone Marrow CD34+ Cells in Young Adult NSG Mice","volume":"3","author":"Wiekmeijer","year":"2014","journal-title":"BioResearch Open Access"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1073\/pnas.0500480102","article-title":"Contingent gene regulatory networks and B cell fate specification","volume":"102","author":"Singh","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1634\/stemcells.2008-0583","article-title":"Busulfan Produces Efficient Human Cell Engraftment in NOD\/LtSz-Scid IL2R\u03b3Null Mice","volume":"27","author":"Hayakawa","year":"2009","journal-title":"Stem Cells"},{"key":"ref_28","first-page":"1384","article-title":"Human cell engraftment after busulfan or irradiation conditioning of NOD\/SCID mice","volume":"91","author":"Ged","year":"2006","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1089\/hum.2014.101","article-title":"Pretransplant Mobilization with Granulocyte Colony-Stimulating Factor Improves B-Cell Reconstitution by Lentiviral Vector Gene Therapy in SCID-X1 Mice","volume":"25","author":"Huston","year":"2014","journal-title":"Human Gene Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1182\/blood-2009-11-253534","article-title":"Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs","volume":"116","author":"Winkler","year":"2010","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.20041385","article-title":"Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist","volume":"201","author":"Broxmeyer","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.omtm.2020.03.016","article-title":"Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID","volume":"17","author":"Vloemans","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/petr.12309","article-title":"A trial of plerixafor adjunctive therapy in allogeneic hematopoietic cell transplantation with minimal conditioning for severe combined immunodeficiency","volume":"18","author":"Dvorak","year":"2014","journal-title":"Pediatric Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.bbmt.2018.03.006","article-title":"A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCR\u03b1\u03b2+ and CD19+ Cell-Depleted Stem Cell Transplantation in Patients with Wiskott-Aldrich Syndrome","volume":"24","author":"Balashov","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/bloodadvances.2019000516","article-title":"Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice","volume":"3","author":"Gao","year":"2019","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.bbmt.2018.12.101","article-title":"A CD117-Amanitin Antibody Drug Conjugate (ADC) Effectively Depletes Human and Non-Human Primate Hematopoietic Stem and Progenitor Cells (HSPCs): Targeted Non-Genotoxic Conditioning for Bone Marrow Transplant","volume":"25","author":"Pearse","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.bbmt.2019.12.139","article-title":"A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates","volume":"26","author":"Uchida","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nbt.3584","article-title":"Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin","volume":"34","author":"Palchaudhuri","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jaci.2020.04.033","article-title":"Efficacy and safety of anti-CD45\u2013saporin as conditioning agent for RAG deficiency","volume":"147","author":"Castiello","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/hum.2015.021","article-title":"211Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy","volume":"26","author":"Burtner","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood-2011-09-380436","article-title":"Durable donor engraftment after radioimmunotherapy using \u03b1-emitter astatine-211\u2013labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-08-4363","article-title":"Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the \u03b1-Emitting Radionuclides Bismuth-213 or Astatine-211","volume":"69","author":"Nakamae","year":"2009","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1126\/science.1149726","article-title":"Efficient Transplantation via Antibody-Based Clearance of Hematopoietic Stem Cell Niches","volume":"318","author":"Czechowicz","year":"2007","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1182\/blood-2010-07-295949","article-title":"Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice","volume":"116","author":"Xue","year":"2010","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"ra105","DOI":"10.1126\/scitranslmed.aae0501","article-title":"Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy","volume":"8","author":"Chhabra","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/j.bbmt.2018.12.172","article-title":"Toxicity-Free Hematopoietic Stem Cell Engraftment Achieved with Anti-CD117 Monoclonal Antibody Conditioning","volume":"25","author":"Agarwal","year":"2019","journal-title":"Biol. Blood Marrow Transplant."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/5\/1077\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:56:17Z","timestamp":1760162177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/10\/5\/1077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["cells10051077"],"URL":"https:\/\/doi.org\/10.3390\/cells10051077","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]}}}